UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

~~May~~July 201, 2022

Date of Report (Date of earliest event reported)

333-188401

Commission File Number

RENAVOTIO, INC.

(Exact name of registrant as specified in its charter)

Nevada		99-0385424
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
601 South Boulder Ave., Suite 600, Tulsa, OK		74119
(Address of principal executive offices)		(Zip Code)

601 South Boulder Ave., Suite 600, Tulsa, OK		74119
(Address of principal executive offices)		(Zip Code)

(888) 928-1312

(Registrant’'s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Renavotio, Inc. is referred to herein as “Renavotio”, “we”, “our”, or “us”.

ITEM 81.01. ~~OTHER~~ENTRY ~~EVENTS~~INTO A MATERIAL DEFINTIVE AGREEMENT

OnPromissory ~~May~~Note ~~20, 2022, Renavotio Medical, LLC, an Oklahoma Limited Liability Company~~ and ~~our~~Securities ~~wholly~~Purchase ~~owned subsidiary (“Renavotio Medical”), and Kyocera Medical Technologies, Inc , a California corporation (“Kyocera”), completed a Reseller~~ Agreement ~~between~~with Tysadco ~~the two companies. Kyocera is in the business of 3D designing~~Partners, ~~manufacturing,~~LLC and distributing products in the trauma, spine and orthopedic surgery areas (the “Products”). Renavotio Medical, referred to in the Agreement as the “Distributor”, is in the business of distributing the Products as the Reseller in the Agreement. Pursuant to the Agreement, Kyocera has appointed Renavotio Medical as the exclusive distributor of the Products in the “Territory”, which is defined as the following countries for which Renavotio will be the exclusive distributor: Bahrain; Iraq; Kuwait; Oman; Saudi Arabia; and the United Arab Emirates. As the exclusive distributor, Renavotio Medical will pay the agreed to cost of products and resell to its targeted clients as agreed in the exclusive territory assigned to Renavotio Medical.

~~ITEM~~On 9July 1, 2022, we entered into a 10% Promissory Note (the “Note”) attached hereto as Exhibit 10.011 (and related July 1, 2022 Securities Purchase Agreement attached hereto as Exhibit 10.2) ~~FINANCIAL~~with ~~STATEMENTS~~Tysadco &Partners, ~~EXHIBITS~~LLC, a New York Limited Liability Company, for the Principal Amount of $50,000, an Original Issue Discount of $5,000, a Maturity Date of July 1, 2023, and a conversion rate of 80% multiplied by the lowest VWAP for our Common Stock during the ten (10) Trading Day period ending on the latest complete trading day prior to the conversion date.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Settlement Agreement with Geneva Roth Remark Holdings, Inc.

2On July 6, 2022, in connection with a July 26, 2021 Convertible Promissory Note (the “Note”) with Geneva Roth Remark Holdings, Inc. (“Geneva”), we agreed to pay Geneva $98,000 by July 18, 2022 in full payment of the Note.

~~SIGNATURES~~ITEM 9.01. FINANCIAL STATMENTS & EXHIBITS

~~Pursuant~~(a) toExhibits. ~~the~~The ~~requirements~~following ofexhibits are ~~the~~filed ~~Securities~~with ~~Exchange Act of 1934, the registrant has duly caused~~ this ~~report~~Current toReport ~~be signed~~ on ~~its~~Form ~~behalf by the undersigned hereunto duly authorized.~~8-K:

Dated: May 25, 2022	By:	/s/ William Robinson
Exhibit No.		Description
		William Robinson
10.1		7/1/22 Promissory Note with Tysadco Partners, LLC*
		Chief Executive Officer
10.2		7/1/22 Securities Purchase Agreement with Tysadco Partners, LLC*
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).*
* Filed herein

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 7, 2022	By:	/s/ William Robinson
		William Robinson
		Chief Executive Officer

Filing Compare · RENAVOTIO, INC.